Mpl胞质酪氨酸残基在小鼠造血与骨髓增殖性疾病中的体内差异作用
该研究在小鼠生殖系中引入Mpl胞质结构域C端三个酪氨酸残基(Y565、Y599、Y604)的突变,发现Mpl-Y599是稳态血小板生成、巨核细胞生成及造血干细胞数量与功能所必需,且骨髓增殖性肿瘤中的血小板增多依赖完整的Mpl-Y599;而Mpl-Y565负向调节Tpo反应,其突变导致稳态及骨髓抑制后巨核细胞生成过多,并加重骨髓增殖性肿瘤相关血小板增多。
要点
- Mpl-Y599突变导致血小板减少、巨核细胞生成缺陷及造血干细胞数量与功能降低。
- 骨髓增殖性肿瘤模型中血小板增多依赖完整的Mpl-Y599。
- Mpl-Y565突变导致稳态及骨髓抑制后巨核细胞生成过多,并加重骨髓增殖性肿瘤相关血小板增多。
核心结论
- Mpl-Y599是稳态造血及骨髓增殖性肿瘤血小板增多所必需的,而Mpl-Y565负向调节Tpo反应。
研究设计与样本
- 在小鼠生殖系中引入Mpl胞质结构域C端酪氨酸残基Y565、Y599和Y604的突变,并在稳态、骨髓抑制及骨髓增殖性肿瘤模型中进行体内分析。
主要发现
- Mpl-Y599突变导致血小板减少、巨核细胞生成缺陷、造血干细胞数量与功能降低及对骨髓抑制的反应减弱。
- 在骨髓增殖性肿瘤模型中,血小板增多依赖完整的Mpl-Y599。
- Mpl-Y565突变导致稳态及骨髓抑制后巨核细胞生成过多,并加重骨髓增殖性肿瘤相关血小板增多。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Thrombopoietin (Tpo), which binds to its specific receptor, the Mpl protein, is the major cytokine regulator of megakaryopoiesis and circulating platelet number. Tpo binding to Mpl triggers activation of Janus kinase 2 (Jak2) and phosphorylation of the receptor, as well as activation of several intracellular signalling cascades that mediate cellular responses. Three tyrosine (Y) residues in the C-terminal region of the Mpl intracellular domain have been implicated as sites of phosphorylation required for regulation of major Tpo-stimulated signalling pathways: Mpl-Y565, Mpl-Y599 and Mpl-Y604. Here, we have introduced mutations in the mouse germline and report a consistent physiological requirement for Mpl-Y599, mutation of which resulted in thrombocytopenia, deficient megakaryopoiesis, low hematopoietic stem cell (HSC) number and function, and attenuated responses to myelosuppression. We further show that in models of myeloproliferative neoplasms (MPN), where Mpl is required for pathogenesis, thrombocytosis was dependent on intact Mpl-Y599. In contrast, Mpl-Y565 was required for negative regulation of Tpo responses; mutation of this residue resulted in excess megakaryopoiesis at steady-state and in response to myelosuppression, and exacerbated thrombocytosis associated with MPN.
引用
- Behrens K, Kauppi M, Viney EM, et al. Differential in vivo roles of Mpl cytoplasmic tyrosine residues in murine hematopoiesis and myeloproliferative disease. Leukemia. 2024. PMID: 38491305. doi:10.1038/s41375-024-02219-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。